New became the norm at Cryoport this year. The company announced new partnerships, new product lines, and new services seemingly every week. On top of these exciting developments were notable milestones in earnings and growth. Here, we share a quick recap of our biggest moments in 2019 – but please pardon us if we’re brief, as we’re busy working on what’s next.
Cryoport Acquires Cryogene, Expands Into Biostorage
With the approximately $20 million purchase of Cryogene strategically located near Houston, Texas, Cryoport now offers biostorage services. Cryogene is an FDA audited facility with a blue-chip roster of long-term clients. Read more
2019 Q1, Q2, and Q3 Results Exceed Expectations
The first three quarters of 2019 marked impressive year-over-year gains. Q1 finished with a 65% revenue increase compared to Q1 2018; Q2 reported an 83% revenue increase; and Q3 reported an 81% revenue increase. The company credited this success to several new partnerships, increased industry activity from both commercial and clinical therapies, as well as new products and services.
Cryoport Announces More Than $63M in Capital Raised to Support Company Mission
The company also announced public offering of common stock. Cryoport's offering enables the company to continue to fund our organic growth as well execute on future acquisitions. Read more
Cryoport Opens Global Logistics Center in Amsterdam
The new state-of-the-art Global Logistics Center in Amsterdam strategically added to Cryoport's global network supporting the distribution of biopharmaceutical products requiring exacting temperature and condition controls. Read more
Cryoport Introduces Cell & Gene Industry's First Dedicated Shipper for Advanced Therapies
Cryoport's new line of Advanced Therapy Shippers™ was launched following strong client demand and in anticipation of more stringent government regulations. This first-of-its-kind Cryoport Express™ shipper reduces the potential risk of cross contamination of materials during use, delivery and distribution of biopharmaceutical materials supporting advanced cell and gene therapies.
Cryoport's Reproductive Medicine Segment Record Revenue
The company's CryoStork branded reproductive medicine segment revenue notably increased in 2019, with a 56% increase in Q1 compared to the same period during the previous year. Q2 and Q3 saw 34% and 26% increases compared to 2018, respectively. Expanded awareness of the CryoStork platform, in addition to new and maturing relationships with large clinic networks, contributed to Cryostork’s success.
Cryoport Team Rings Nasdaq Closing Bell
Cryoport was honored to be offered to ring the closing bell at Nasdaq this year. See photos and video
Cryoport Publishes Pivotal White Paper on Chain of Compliance™
New regulations are coming that will impact the regenerative medicine industry – and soon. Research labs, pharmaceutical companies, and logistics providers need to adjust their operations as quickly as possible. Our white paper outlines the expected requirements and ways to prepare now. Read the white paper
Cryoport Establishes Partnerships With Major Industry Players, Expanding Connections and Services Across the World
The ecosystem to support regenerative therapies is being built on the run as the expansion of clinical trials and commercially approved products develops globally. To meet the increasing demands of our customers, to ensure the highest quality and depth of services, and to be able to meet future regulatory demands Cryoport has chosen to partner with other leading companies that have competencies that complement ours.
New partnerships agreements were established with the following companies:
Lonza: Lonza is a Swiss-based health sciences company with more than 1,000 locations worldwide. Cryoport was named Lonza’s “preferred partner” in the global transportation of patient tissues. “There is no doubt that this partnership enables us to provide a best-in-class solution to cell and gene therapy companies for manufacturing and supply chain services, allowing us to provide a fully integrated solution that reduces risk and increases transparency,” said Alberto Santagostino, SVP Head of Cell & Gene Technologies, Lonza Pharma & Biotech.
Vineti: The Vineti-Cryoport solution provides biopharmaceutical developers with a pre-integrated SCO and temperature logistics system that offers digital, optimized end-to-end traceability and control. With Vineti’s platform being deployed in more than 300 clinical centers worldwide within the next year, and Cryoport serving more than 400 clinical trials and three commercialized therapies, the collaboration between the two companies provides a broad-based global solution.
CalAmp: Global technology solutions provider CalAmp is working with Cryoport on an advanced supply chain monitoring system. “The solutions we are working with CalAmp to develop should enable us to add offerings that will significantly reduce the risks associated with the temperature-controlled transportation of commodities in our markets,” said Cryoport CEO Jerrell Shelton.
EVERSANA: Cryoport’s alliance with EVERSANA™, which provides global services to more than 500 life science organizations worldwide, creates a fully integrated regenerative medicine supply chain solution.
Dacos A/S: The high-tech life sciences company based in Denmark partnered with Cryoport to support Dacos’s biopharmaceutical clients and products